UTHR
UNITED THERAPEUTICS Corp
$549.87
+0.40%
$23.2B
No data for this timeframe.
Vol
Market Cap$23.2B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (82%)
Inst. Holders9 funds
Inst. Value$3.9B
Inst. Activity2 buys / 0 sells
Insider Activity1B / 16S
Insider Net $-$3.9M
Reddit Sentiment50° Neutral
SEC Reports20
Recent Activity
Jun 5, 2026
SEC
Three top insiders at United Therapeutics (CEO, CFO, General Counsel) sold a total of $391K in open-market shares over a
CLUSTER — Impact 2/10
Jun 4, 2026
SEC
Three top executives at United Therapeutics (CEO, CFO, General Counsel) collectively sold $1.11M in open-market shares o
CLUSTER — Impact 3/10
Jun 4, 2026
SEC
CEO Martine Rothblatt and CFO James Edgemond executed derivative exercises and sold a combined ~$1.0M in open-market sha
CLUSTER — Impact 2/10
Jun 4, 2026
Insider
MAHON PAUL A sold 8,300 shares
EVP & GENERAL COUNSEL @ $0.00 ($0.00)
Jun 4, 2026
Insider
MAHON PAUL A sold 200 shares
EVP & GENERAL COUNSEL @ $539.76 ($108.0K)
Jun 4, 2026
Insider
MAHON PAUL A sold 8,300 shares
EVP & GENERAL COUNSEL @ $146.03 ($1.2M)
Inst.
NORGES BANK — NEW
602,191 shares ($293.4M)
Inst.
FMR LLC — ADD
403,830 shares ($196.8M)
Price Targets
$665.23
+21.0% upside
Strong Buy
Current $549.87
Low $516.00
Median $685.00
High $750.00
13 analysts
$516.00
$750.00
Analyst Ratings
6Strong Buy
12Buy
4Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 7, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| May 7, 2026 | Wells Fargo | UPGRADE | Equal-Weight → Overweight |
| Apr 10, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight → Equal-Weight |
| Mar 31, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 31, 2026 | Wells Fargo | MAINTAIN | Equal-Weight → Equal-Weight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $6.96 ▼ -1.6% | $6.07 — $7.76 | 9% YoY | 12 |
| Next Q | $7.13 | $6.08 — $8.08 | -0% YoY | 12 |
| Current FY | $27.31 ▼ -4.4% | $24.93 — $29.68 | -2% YoY | 14 |
| Next FY | $31.62 ▼ -4.0% | $23.10 — $38.60 | 16% YoY | 14 |
Latest Reports
NEUTRAL
CLUSTER
2/10
Three top insiders at United Therapeutics (CEO, CFO, General Counsel) sold a total of $391K in open-market shares over a
Jun 5, 2026
NEUTRAL
CLUSTER
3/10
Three top executives at United Therapeutics (CEO, CFO, General Counsel) collectively sold $1.11M in open-market shares o
Jun 4, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $2.0B | — |
| RENAISSANCE TECHNOLOGIES LLC | $930.3M | — |
| NORGES BANK | $293.4M | NEW |
| FMR LLC | $196.8M | ADD |
| MORGAN STANLEY | $189.7M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | MAHON PAUL | M | $0.00 |
| Jun 4, 2026 | MAHON PAUL | SELL | $108.0K |
| Jun 4, 2026 | MAHON PAUL | M | $1.2M |
| Jun 4, 2026 | ROTHBLATT MARTINE | SELL | $64.7K |
| Jun 4, 2026 | EDGEMOND JAMES | SELL | $64.8K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
9 institutional holders with $3.9B total value (8,082,650 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, NORGES. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 4,176,016 | $2.0B | 51.7% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 1,909,259 | $930.3M | 23.6% | — |
| 3 | NORGES BANK | 602,191 | $293.4M | 7.5% | NEW |
| 4 | FMR LLC | 403,830 | $196.8M | 5.0% | ADD +61.3% |
| 5 | MORGAN STANLEY | 389,275 | $189.7M | 4.8% | TRIM -50.3% |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 289,926 | $141.3M | 3.6% | NEW |
| 7 | BANK OF AMERICA CORP /DE/ | 205,131 | $100.0M | 2.5% | — |
| 8 | WELLS FARGO & COMPANY/MN | 90,940 | $44.3M | 1.1% | TRIM -35.3% |
| 9 | TWO SIGMA INVESTMENTS, LP | 16,082 | $7.8M | 0.2% | ADD +82.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 602,191 | — | $293.4M | 2025-Q4 |
| FMR LLC | ADD | 250,331 | 403,830 | +61.3% | $196.8M | 2025-Q4 |
| FMR LLC | TRIM | 424,240 | 250,331 | -41.0% | $104.9M | 2025-Q3 |
| UBS Group AG | ADD | 104,114 | 155,404 | +49.3% | $65.1M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 120,726 | 78,121 | -35.3% | $32.7M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 8,800 | 16,090 | +82.8% | $6.7M | 2025-Q3 |
| NORGES BANK | EXIT | 474,868 | 0 | -100.0% | $0.00 | 2025-Q3 |
| NORGES BANK | NEW | — | 474,868 | — | $136.5M | 2025-Q2 |
| FMR LLC | TRIM | 1,144,603 | 424,240 | -62.9% | $121.9M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 74,077 | 120,726 | +63.0% | $34.7M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 1,525 | 8,800 | +477.0% | $2.5M | 2025-Q2 |
| UBS Group AG | ADD | 95,066 | 133,317 | +40.2% | $41.1M | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 54,138 | 69,584 | +28.5% | $21.5M | 2025-Q1 |
| NORGES BANK | EXIT | 430,122 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | TRIM | 806,988 | 401,463 | -50.3% | $143.9M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 369,955 | — | $132.6M | 2024-Q3 |
3 unique insiders with 17 transactions. Net insider value: -$3.9M ($863.9K bought, $4.8M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | MAHON PAUL A | EVP & GENERAL COUNSEL | M | 8,300 | $0.00 | $0.00 |
| Jun 4, 2026 | MAHON PAUL A | EVP & GENERAL COUNSEL | SELL | 200 | $539.76 | $108.0K |
| Jun 4, 2026 | MAHON PAUL A | EVP & GENERAL COUNSEL | M | 8,300 | $146.03 | $1.2M |
| Jun 4, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | SELL | 120 | $539.51 | $64.7K |
| Jun 4, 2026 | EDGEMOND JAMES | CFO AND TREASURER | SELL | 120 | $539.64 | $64.8K |
| Jun 4, 2026 | EDGEMOND JAMES | CFO AND TREASURER | M | 10,000 | $117.76 | $1.2M |
| Jun 4, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | M | 9,500 | $0.00 | $0.00 |
| Jun 4, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | M | 9,500 | $146.03 | $1.4M |
| Jun 4, 2026 | EDGEMOND JAMES | CFO AND TREASURER | M | 10,000 | $0.00 | $0.00 |
| Jun 3, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | M | 9,500 | $146.03 | $1.4M |
| Jun 3, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | M | 9,500 | $0.00 | $0.00 |
| Jun 3, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | SELL | 401 | $543.89 | $218.1K |
| Jun 2, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | M | 9,500 | $146.03 | $1.4M |
| Jun 2, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | SELL | 1,160 | $535.69 | $621.4K |
| Jun 2, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | M | 9,500 | $0.00 | $0.00 |
| Jun 1, 2026 | EDGEMOND JAMES | CFO AND TREASURER | M | 10,000 | $117.76 | $1.2M |
| Jun 1, 2026 | EDGEMOND JAMES | CFO AND TREASURER | SELL | 1,440 | $544.96 | $784.7K |
| Jun 1, 2026 | EDGEMOND JAMES | CFO AND TREASURER | M | 10,000 | $0.00 | $0.00 |
| Jun 1, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | M | 9,500 | $146.03 | $1.4M |
| Jun 1, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | SELL | 1,365 | $545.04 | $744.0K |
| Jun 1, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | M | 9,500 | $0.00 | $0.00 |
| May 28, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | M | 9,500 | $146.03 | $1.4M |
| May 28, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | M | 9,500 | $0.00 | $0.00 |
| May 28, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | SELL | 295 | $561.53 | $165.7K |
| May 28, 2026 | EDGEMOND JAMES | CFO AND TREASURER | M | 10,000 | $117.76 | $1.2M |
| May 28, 2026 | EDGEMOND JAMES | CFO AND TREASURER | SELL | 320 | $561.48 | $179.7K |
| May 28, 2026 | EDGEMOND JAMES | CFO AND TREASURER | M | 10,000 | $0.00 | $0.00 |
| May 27, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | M | 9,500 | $146.03 | $1.4M |
| May 27, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | SELL | 1,479 | $570.81 | $844.2K |
| May 27, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | M | 9,500 | $0.00 | $0.00 |
| May 26, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | M | 9,500 | $146.03 | $1.4M |
| May 26, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | SELL | 45 | $560.52 | $25.2K |
| May 26, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | BUY | 1,500 | $575.96 | $863.9K |
| May 26, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | M | 9,500 | $0.00 | $0.00 |
| May 26, 2026 | EDGEMOND JAMES | CFO AND TREASURER | M | 10,000 | $117.76 | $1.2M |
| May 26, 2026 | EDGEMOND JAMES | CFO AND TREASURER | SELL | 25 | $559.58 | $14.0K |
| May 26, 2026 | EDGEMOND JAMES | CFO AND TREASURER | M | 10,000 | $0.00 | $0.00 |
| May 26, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | G | 9,009 | $0.00 | $0.00 |
| May 26, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | G | 2,060 | $0.00 | $0.00 |
| May 26, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | SELL | 1,500 | $575.96 | $863.9K |
| May 22, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | M | 9,500 | $0.00 | $0.00 |
| May 22, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | M | 9,500 | $146.03 | $1.4M |
| May 22, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | SELL | 47 | $563.27 | $26.5K |
| May 21, 2026 | MAHON PAUL A | EVP & GENERAL COUNSEL | SELL | 110 | $555.72 | $61.1K |
| May 21, 2026 | MAHON PAUL A | EVP & GENERAL COUNSEL | M | 300 | $146.03 | $43.8K |
| May 21, 2026 | MAHON PAUL A | EVP & GENERAL COUNSEL | M | 8,300 | $0.00 | $0.00 |
| May 21, 2026 | EDGEMOND JAMES | CFO AND TREASURER | M | 10,000 | $117.76 | $1.2M |
| May 21, 2026 | EDGEMOND JAMES | CFO AND TREASURER | SELL | 40 | $557.85 | $22.3K |
| May 21, 2026 | EDGEMOND JAMES | CFO AND TREASURER | M | 10,000 | $0.00 | $0.00 |
| May 20, 2026 | ROTHBLATT MARTINE A | Chairperson & CEO | M | 9,500 | $0.00 | $0.00 |
20 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 20 neutral. Avg impact: 2.3/10.
NEUTRAL
CLUSTER
2/10
Three top insiders at United Therapeutics (CEO, CFO, General Counsel) sold a total of $391K in open-
Jun 5, 2026
NEUTRAL
CLUSTER
3/10
Three top executives at United Therapeutics (CEO, CFO, General Counsel) collectively sold $1.11M in
Jun 4, 2026
NEUTRAL
CLUSTER
2/10
CEO Martine Rothblatt and CFO James Edgemond executed derivative exercises and sold a combined ~$1.0
Jun 4, 2026
NEUTRAL
CLUSTER
2/10
CEO Martine Rothblatt and CFO James Edgemond sold a combined ~$1.41M in UTHR shares over five tradin
Jun 3, 2026
NEUTRAL
CLUSTER
2/10
CEO Martine Rothblatt and two other insiders executed a series of transactions over a 7-day window,
May 29, 2026
NEUTRAL
CLUSTER
3/10
The CEO made an open-market purchase of $864K alongside net open-market sales of ~$870K by the CEO,
May 28, 2026
NEUTRAL
CLUSTER
2/10
CEO Martine Rothblatt made a $864K open-market purchase of 1,500 shares at $575.96 on 2026-05-26, al
May 27, 2026
NEUTRAL
CLUSTER
3/10
Three top insiders at United Therapeutics (CEO, CFO, General Counsel) sold a combined ~$110K in open
May 26, 2026
NEUTRAL
CLUSTER
2/10
Three top executives (CEO, EVP/GC, CFO) exercised stock options and sold a minimal number of shares
May 26, 2026
NEUTRAL
CLUSTER
2/10
Three UTHR insiders including the CEO, CFO, and EVP & General Counsel executed a series of option ex
May 22, 2026
NEUTRAL
CLUSTER
2/10
Insider cluster at United Therapeutics shows CEO and CFO selling small amounts of stock after option
May 21, 2026
NEUTRAL
CLUSTER
2/10
UTHR's CEO, CFO, and a director sold shares worth $271K in aggregate over a week following Q1 2026 e
May 19, 2026
NEUTRAL
CLUSTER
2/10
CEO Martine Rothblatt, CFO James Edgemond, and Director Nilda Mesa sold a total of ~$1.03M in UTHR s
May 18, 2026
NEUTRAL
CLUSTER
2/10
Four UTHR insiders (CEO, CFO, EVP, Director) sold a total of ~$1.04M in open-market sales over a 7-d
May 15, 2026
NEUTRAL
CLUSTER
4/10
A cluster of insider sales at United Therapeutics (UTHR) totaling $1.72M occurred within 8 days of a
May 14, 2026
NEUTRAL
CLUSTER
2/10
Three top executives at United Therapeutics (CEO, CFO, General Counsel) executed option exercises an
May 12, 2026
NEUTRAL
CLUSTER
2/10
Three insiders at United Therapeutics sold a total of $377K in open-market sales over a 7-day window
May 11, 2026
NEUTRAL
CLUSTER
2/10
CEO and CFO exercised stock options and sold a small number of shares (total ~$558K) coincident with
May 6, 2026
NEUTRAL
CLUSTER
2/10
Insider trading cluster at United Therapeutics shows minimal open-market sales totaling ~$1.92M agai
May 4, 2026
NEUTRAL
144
3/10
Officer James Edgemond files Form 144 to sell 148,750 shares ($84.8M) from option exercises under a
May 4, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (82% buy). Based on 22 analysts: 6 strong buy, 12 buy, 4 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$665.23 mean target
+21.0% upside
Strong Buy (1.60)
$516.00 Low
$750.00 High
| Metric | Value |
|---|---|
| Current Price | $549.87 |
| Target Low | $516.00 |
| Target Mean | $665.23 |
| Target Median | $685.00 |
| Target High | $750.00 |
| # Analysts | 13 |
| Recommendation | Strong Buy (1.60) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$6.96 | $6.07 | $7.76 | 8.6% | -1.6% | 6↑ 5↓ | $0.8B | 1.5% | 12 |
| Next Q 2026-09-30 |
$7.13 | $6.08 | $8.08 | -0.4% | -0.3% | 5↑ 6↓ | $0.8B | 3.1% | 12 |
| Current FY 2026-12-31 |
$27.31 | $24.93 | $29.68 | -2.0% | -4.4% | 2↑ 10↓ | $3.3B | 2.5% | 14 |
| Next FY 2027-12-31 |
$31.62 | $23.10 | $38.60 | 15.8% | -4.0% | 5↑ 7↓ | $3.7B | 13.4% | 14 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $6.959 | |
| 7d ago | $6.959 | |
| 30d ago | $7.071 | -0.112 |
| 60d ago | $6.929 | +0.029 |
| 90d ago | $6.982 | -0.023 |
9 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 7, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 7, 2026 | Wells Fargo | UPGRADE | Equal-Weight | Overweight |
| Apr 10, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Mar 31, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 31, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Mar 31, 2026 | B of A Securities | MAINTAIN | Neutral | Neutral |
| Mar 30, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Mar 23, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Mar 12, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Mar 5, 2026 | UBS | MAINTAIN | Buy | Buy |
| Feb 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 26, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Feb 26, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Feb 26, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 26, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Jan 6, 2026 | UBS | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 12 | 4 | 0 | 0 | 82% | |
| May 1, 2026 | 7 | 10 | 5 | 0 | 0 | 77% | |
| Apr 1, 2026 | 7 | 9 | 5 | 0 | 0 | 76% | |
| Mar 1, 2026 | 7 | 9 | 5 | 0 | 0 | 76% | |
| Feb 1, 2026 | 7 | 8 | 6 | 0 | 0 | 71% | |
| Jan 1, 2026 | 7 | 8 | 6 | 0 | 0 | 71% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 30, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 30, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Market Close Report - Monday, March 30, 2026
▲ 1
💬 0
⚡ 0.5
May 11, 2026
dark_pool
Dark Pool: UTHR — 0.4M shares, 20,219 trades
Week starting 2026-05-11. Total ATS volume: 406,018 shares across 20,219 trades.
May 7, 2026
Clinical Trial
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Phase Phase 3 — TERMINATED
May 7, 2026
Clinical Trial
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Phase Phase 3 — COMPLETED
May 6, 2026
earnings_calendar
UTHR Q1 2026 Earnings Before Market Open — 2026-05-06
May 4, 2026
dark_pool
Dark Pool: UTHR — 0.7M shares, 29,178 trades
Week starting 2026-05-04. Total ATS volume: 694,070 shares across 29,178 trades.
May 1, 2026
clinical_trial_readout
Results Pending: Inhaled Treprostinil (Phase 3) — Completed 88d ago
Trial: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Sponsor: United Therapeutics
Phase: Phase 3
Apr 27, 2026
dark_pool
Dark Pool: UTHR — 0.3M shares, 18,891 trades
Week starting 2026-04-27. Total ATS volume: 278,459 shares across 18,891 trades.
Apr 20, 2026
dark_pool
Dark Pool: UTHR — 0.4M shares, 21,918 trades
Week starting 2026-04-20. Total ATS volume: 434,428 shares across 21,918 trades.
Apr 20, 2026
short_interest
FTD: UTHR — 1,400 shares ($0.8M) failed to deliver
Settlement: 20260420, Price: $588.38, FTD Value: $823,732, UNITED THERAPEUTICS CORP
Apr 14, 2026
Clinical Trial
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Phase Phase 3 — COMPLETED
Apr 13, 2026
dark_pool
Dark Pool: UTHR — 0.6M shares, 28,108 trades
Week starting 2026-04-13. Total ATS volume: 575,150 shares across 28,108 trades.
Apr 10, 2026
short_interest
FTD: UTHR — 10,232 shares ($5.9M) failed to deliver
Settlement: 20260410, Price: $574.77, FTD Value: $5,881,046.64, UNITED THERAPEUTICS CORP
Apr 6, 2026
dark_pool
Dark Pool: UTHR — 0.6M shares, 36,513 trades
Week starting 2026-04-06. Total ATS volume: 649,739 shares across 36,513 trades.
Apr 1, 2026
clinical_trial_readout
Results Pending: Inhaled Treprostinil (Phase 3) — Completed 58d ago
Trial: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Sponsor: United Therapeutics
Phase: Phase 3
Mar 30, 2026
clinical_trial_readout
Results Pending: Inhaled Treprostinil (Phase 3) — Completed 56d ago
Trial: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Sponsor: United Therapeutics
Phase: Phase 3
Mar 30, 2026
clinical_trial_readout
Results Pending: Ralinepag (Phase 3) — Completed 89d ago
Trial: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Sponsor: United Therapeutics
Phase: Phase
Mar 30, 2026
dark_pool
Dark Pool: UTHR — 1.1M shares, 44,417 trades
Week starting 2026-03-30. Total ATS volume: 1,071,858 shares across 44,417 trades.
Mar 30, 2026
short_volume
Short Volume: UTHR — 67.9% short (0.4M / 0.6M)
Short: 420,653 | Exempt: 1,356 | TRF Vol: 619,121 | Short Ratio: 67.9% | Off-exchange volume (dark pool + OTC)
Mar 4, 2026
Clinical Trial
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase Phase 3 — COMPLETED